Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain

• Intensity of chest pain episodes [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  how strong the chest pain episodes are
• Sensory thresholds for first sensation [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  the balloon distension level when a sensation is first felt
• Sensory thresholds for discomfort [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  the balloon distension level when discomfort is felt
• Sensory thresholds for pain [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  the balloon distension level when pain is felt
• duration of chest pain episodes [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  how long the chest pain episodes last

The purpose of this study is to investigate a new treatment for non-cardiac chest pain (NCCP) related to gastrointestinal reflux disease (GERD), called Dexilant. The investigators would like to test its effectiveness in treating NCCP.

The patient will undergo esophageal balloon distention testing (EBDT) before and after taking the new treatment for one month (Dexilant). EBDT evaluates the sensation and mechanical properties of the esophagus. A catheter with a deflated balloon is placed through the mouth and into the esophagus and the balloon is inflated with water. ECG and labs will be done throughout the study as a measurement of safety.

• Chest Pain
• Gastrointestinal Reflux Disease

• Drug: Dexilant
  60mg of Dexilant QD for 12 weeks
• Drug: Dexilant Placebo
  60mg of Dexilant placebo QD for 12 weeks
  Other Name: Dexlansoprazole

• Active Comparator: Dexilant
  60mg of Dexilant QD for 12 weeks
  Intervention: Drug: Dexilant
• Placebo Comparator: Placebo
  60mg of Dexilant placebo QD for 12 weeks
  Intervention: Drug: Dexilant Placebo

Inclusion Criteria:

1. Aged 18-75 years
2. NERD, or GERD LA Class A-B (endoscopy)
3. Subjects with positive pH testing
4. At least one episode of chest pain a week in the past month
5. Previous negative cardiac evaluation (EKG ± stress test ± coronary angiogram)
6. Negative esophageal evaluation for a motility disorder (Nutcracker esophagus, achalasia)

Exclusion Criteria:

1. Subjects requiring narcotics or other pain medications, Subjects with known LA class C-D, Barrett's esophagus or peptic stricture on endoscopy
2. Subjects with previous upper gastrointestinal surgery
3. Pregnancy
4. Subjects with diabetes, neuromuscular disorders, or other severe co-morbidities
5. (Cardiovascular, respiratory, renal, hepatic, hematologic, endocrine, neurologic, and psychiatric).
6. Subjects with upper airway symptoms (such as hoarseness, wheezing, laryngospasm).
7. Medications such as baclofen, and prokinetic agents.
8. History of substance abuse